id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-E-1288-0007,FDA,FDA-2024-E-1288,Determination of Regulatory Review Period for Purposes of Patent Extension; ADZYNMA,Notice,Determinations,2025-12-29T05:00:00Z,2025,12,2025-12-29T05:00:00Z,2026-02-28T04:59:59Z,2025-12-29T19:39:03Z,2025-23864,0,0,09000064b910acd7
FDA-2024-E-1288-0006,FDA,FDA-2024-E-1288,Letter to Troutman Pepper Hamilton Sanders LLP,Other,Letter(s),2025-08-27T04:00:00Z,2025,8,2025-08-27T04:00:00Z,,2025-08-27T22:13:56Z,,0,0,09000064b8f1acfa
FDA-2024-E-1288-0005,FDA,FDA-2024-E-1288,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2025-08-19T04:00:00Z,2025,8,2025-08-19T04:00:00Z,,2025-08-19T21:05:57Z,,0,0,09000064b8f06081
FDA-2024-E-1288-0004,FDA,FDA-2024-E-1288,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-07-16T04:00:00Z,2025,7,2025-07-16T04:00:00Z,,2025-07-16T22:22:27Z,,0,0,09000064b8e7b6a7
FDA-2024-E-1288-0003,FDA,FDA-2024-E-1288,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2025-07-02T04:00:00Z,2025,7,2025-07-02T04:00:00Z,,2025-07-02T18:57:21Z,,0,0,09000064b8e434de
FDA-2024-E-1288-0001,FDA,FDA-2024-E-1288,Letter from U. S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-03-18T04:00:00Z,2024,3,2024-03-18T04:00:00Z,,2024-03-18T15:56:34Z,,0,0,0900006486481b4d
FDA-2024-E-1288-0002,FDA,FDA-2024-E-1288,"Patent Term Extension Application for ADZYNMA Patent No 10,758,599",Other,Application,2024-03-18T04:00:00Z,2024,3,2024-03-18T04:00:00Z,,2024-03-18T15:56:38Z,,0,0,0900006486481b4f